Clinical effects and toxicity of interleukin-2 in patients with cancer

M. T. Lotze, Y. L. Matory, A. A. Rayner, S. E. Ettinghausen, John Vetto, C. A. Seipp, S. A. Rosenberg

Research output: Contribution to journalArticle

277 Citations (Scopus)

Abstract

Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have substantial activity alone or in combination with the adoptive transfer of lymphokine-activated killer cells in murine tumor models. IL-2 derived from both natural (Jurkat human T-cell) and recombinant (Escherichia coli) sources has been studied in Phase I protocols designed to evaluate toxicity in patients with a variety of solid tumors and to ascertain improvement in clinical parameters and immunologic status. A total of 16 patients (7 with acquired immune deficiency syndrome [AIDS] and 9 with non-AIDS malignancies) were treated with Jurkat derived IL-2. The total maximum dose (1.3 x 105 U/kg) was limited only by supply of this reagent. A total of 25 patients have been treated with recombinant IL-2 (RIL-2) alone. Dose-limiting toxicity manifesed by marked malaise and weight gain was achieved with doses of RIL-2 of 106 U/kg as a single bolus or 3000 U/kg/hr. IL-2 could be administered intraperitoneally with similar toxicity. Minimal renal or hepatic toxicity was demonstrated. Hematologic toxicity was limited to mild anemia (25/25), thrombocytopenia (10/25), and marked reversible eosinophilia (15/25). Pronounced weight gain greater than 2 kg (16/25) occurred in most patients, primarily those who received cumulative doses of greater than 1-3 x 105 U/kg of IL-2. The weight gain amounted to as much as 10% to 20% of the pretreatment weight over 3 weeks of treatment and limited our ability to give higher doses. Two partial responses (>50% decrease in cross sectional diameters) were seen in two patients with melanoma metastatic to the lung.

Original languageEnglish (US)
Pages (from-to)2764-2772
Number of pages9
JournalCancer
Volume58
Issue number12
StatePublished - 1986
Externally publishedYes

Fingerprint

Interleukin-2
Neoplasms
Weight Gain
T-Lymphocytes
Lymphokine-Activated Killer Cells
Adoptive Transfer
Eosinophilia
Thrombocytopenia
Anemia
Melanoma
Glycoproteins
Acquired Immunodeficiency Syndrome
Escherichia coli
Kidney
Weights and Measures
Lung
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J., Seipp, C. A., & Rosenberg, S. A. (1986). Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer, 58(12), 2764-2772.

Clinical effects and toxicity of interleukin-2 in patients with cancer. / Lotze, M. T.; Matory, Y. L.; Rayner, A. A.; Ettinghausen, S. E.; Vetto, John; Seipp, C. A.; Rosenberg, S. A.

In: Cancer, Vol. 58, No. 12, 1986, p. 2764-2772.

Research output: Contribution to journalArticle

Lotze, MT, Matory, YL, Rayner, AA, Ettinghausen, SE, Vetto, J, Seipp, CA & Rosenberg, SA 1986, 'Clinical effects and toxicity of interleukin-2 in patients with cancer', Cancer, vol. 58, no. 12, pp. 2764-2772.
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto J, Seipp CA et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58(12):2764-2772.
Lotze, M. T. ; Matory, Y. L. ; Rayner, A. A. ; Ettinghausen, S. E. ; Vetto, John ; Seipp, C. A. ; Rosenberg, S. A. / Clinical effects and toxicity of interleukin-2 in patients with cancer. In: Cancer. 1986 ; Vol. 58, No. 12. pp. 2764-2772.
@article{3da5f14c1ee4401e9fcf98d3f116e374,
title = "Clinical effects and toxicity of interleukin-2 in patients with cancer",
abstract = "Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have substantial activity alone or in combination with the adoptive transfer of lymphokine-activated killer cells in murine tumor models. IL-2 derived from both natural (Jurkat human T-cell) and recombinant (Escherichia coli) sources has been studied in Phase I protocols designed to evaluate toxicity in patients with a variety of solid tumors and to ascertain improvement in clinical parameters and immunologic status. A total of 16 patients (7 with acquired immune deficiency syndrome [AIDS] and 9 with non-AIDS malignancies) were treated with Jurkat derived IL-2. The total maximum dose (1.3 x 105 U/kg) was limited only by supply of this reagent. A total of 25 patients have been treated with recombinant IL-2 (RIL-2) alone. Dose-limiting toxicity manifesed by marked malaise and weight gain was achieved with doses of RIL-2 of 106 U/kg as a single bolus or 3000 U/kg/hr. IL-2 could be administered intraperitoneally with similar toxicity. Minimal renal or hepatic toxicity was demonstrated. Hematologic toxicity was limited to mild anemia (25/25), thrombocytopenia (10/25), and marked reversible eosinophilia (15/25). Pronounced weight gain greater than 2 kg (16/25) occurred in most patients, primarily those who received cumulative doses of greater than 1-3 x 105 U/kg of IL-2. The weight gain amounted to as much as 10{\%} to 20{\%} of the pretreatment weight over 3 weeks of treatment and limited our ability to give higher doses. Two partial responses (>50{\%} decrease in cross sectional diameters) were seen in two patients with melanoma metastatic to the lung.",
author = "Lotze, {M. T.} and Matory, {Y. L.} and Rayner, {A. A.} and Ettinghausen, {S. E.} and John Vetto and Seipp, {C. A.} and Rosenberg, {S. A.}",
year = "1986",
language = "English (US)",
volume = "58",
pages = "2764--2772",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Clinical effects and toxicity of interleukin-2 in patients with cancer

AU - Lotze, M. T.

AU - Matory, Y. L.

AU - Rayner, A. A.

AU - Ettinghausen, S. E.

AU - Vetto, John

AU - Seipp, C. A.

AU - Rosenberg, S. A.

PY - 1986

Y1 - 1986

N2 - Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have substantial activity alone or in combination with the adoptive transfer of lymphokine-activated killer cells in murine tumor models. IL-2 derived from both natural (Jurkat human T-cell) and recombinant (Escherichia coli) sources has been studied in Phase I protocols designed to evaluate toxicity in patients with a variety of solid tumors and to ascertain improvement in clinical parameters and immunologic status. A total of 16 patients (7 with acquired immune deficiency syndrome [AIDS] and 9 with non-AIDS malignancies) were treated with Jurkat derived IL-2. The total maximum dose (1.3 x 105 U/kg) was limited only by supply of this reagent. A total of 25 patients have been treated with recombinant IL-2 (RIL-2) alone. Dose-limiting toxicity manifesed by marked malaise and weight gain was achieved with doses of RIL-2 of 106 U/kg as a single bolus or 3000 U/kg/hr. IL-2 could be administered intraperitoneally with similar toxicity. Minimal renal or hepatic toxicity was demonstrated. Hematologic toxicity was limited to mild anemia (25/25), thrombocytopenia (10/25), and marked reversible eosinophilia (15/25). Pronounced weight gain greater than 2 kg (16/25) occurred in most patients, primarily those who received cumulative doses of greater than 1-3 x 105 U/kg of IL-2. The weight gain amounted to as much as 10% to 20% of the pretreatment weight over 3 weeks of treatment and limited our ability to give higher doses. Two partial responses (>50% decrease in cross sectional diameters) were seen in two patients with melanoma metastatic to the lung.

AB - Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human T-cells during an immune response. IL-2 has been demonstrated to have substantial activity alone or in combination with the adoptive transfer of lymphokine-activated killer cells in murine tumor models. IL-2 derived from both natural (Jurkat human T-cell) and recombinant (Escherichia coli) sources has been studied in Phase I protocols designed to evaluate toxicity in patients with a variety of solid tumors and to ascertain improvement in clinical parameters and immunologic status. A total of 16 patients (7 with acquired immune deficiency syndrome [AIDS] and 9 with non-AIDS malignancies) were treated with Jurkat derived IL-2. The total maximum dose (1.3 x 105 U/kg) was limited only by supply of this reagent. A total of 25 patients have been treated with recombinant IL-2 (RIL-2) alone. Dose-limiting toxicity manifesed by marked malaise and weight gain was achieved with doses of RIL-2 of 106 U/kg as a single bolus or 3000 U/kg/hr. IL-2 could be administered intraperitoneally with similar toxicity. Minimal renal or hepatic toxicity was demonstrated. Hematologic toxicity was limited to mild anemia (25/25), thrombocytopenia (10/25), and marked reversible eosinophilia (15/25). Pronounced weight gain greater than 2 kg (16/25) occurred in most patients, primarily those who received cumulative doses of greater than 1-3 x 105 U/kg of IL-2. The weight gain amounted to as much as 10% to 20% of the pretreatment weight over 3 weeks of treatment and limited our ability to give higher doses. Two partial responses (>50% decrease in cross sectional diameters) were seen in two patients with melanoma metastatic to the lung.

UR - http://www.scopus.com/inward/record.url?scp=0022871958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022871958&partnerID=8YFLogxK

M3 - Article

C2 - 3490903

AN - SCOPUS:0022871958

VL - 58

SP - 2764

EP - 2772

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -